Search Results
Your search for ,maY matches 16444 pages
Showing 3801 - 3850Report Documents Third Known Case of HIV Remission Involving Stem Cell Transplant
A woman with human immunodeficiency virus (HIV) who received a cord blood stem cell transplant to treat acute myeloid leukemia has had no detectable levels of HIV for 14 months, despite cessation of antiretroviral therapy, according to research presented at the Conference on Retroviruses and...
Potential Use of FDG-PET Findings in Reducing Duration of Immunotherapy in Patients With Advanced Melanoma
In a Danish retrospective study reported in the International Journal of Cancer, Ellebaek et al found that patients with advanced melanoma responding to PD-1 inhibitor therapy who stopped treatment within 18 months had improved survival outcomes when fluorodeoxyglucose (F-18) positron-emission...
Are Patients Undergoing Active Cancer Treatment More Likely to Believe COVID-19 Misinformation?
Patients with cancer undergoing active treatment were more likely to believe misinformation related to COVID-19 than those without a history of cancer, according to a new study published by Guidry et al in Patient Education and Counseling. “These findings help us better understand the threat of...
H1-Antihistamine Use and Risk of Hepatocellular Carcinoma in Persons With Hepatitis B Virus, Hepatitis C Virus, or Dual Infection
In a Taiwanese study reported in the Journal of Clinical Oncology, Shen et al found that use of H1-antihistamines was associated with reduced risk of hepatocellular carcinoma in patients with hepatitis B virus (HBV), hepatitis C virus (HCV), or dual HBV/HCV infection. Study Details The study...
Comprehensive Genetic Risk Score May Predict Risk of Developing Metastatic Prostate Cancer or Death From Prostate Cancer Across Diverse Populations
A new screening tool (called PHS290) that incorporates 290 inherited genetic variants associated with prostate cancer was able to accurately identify people with high vs low lifetime risks of developing metastatic prostate cancer or dying from prostate cancer. These findings of a genetic risk...
Neoadjuvant Atezolizumab Plus Gemcitabine and Cisplatin in Muscle-Invasive Bladder Cancer
In a phase II trial reported in the Journal of Clinical Oncology, Funt et al found that the combination of neoadjuvant atezolizumab with gemcitabine and cisplatin resulted in a high rate of tumor downstaging to < pT2N0 in patients with muscle-invasive bladder cancer. Study Details The U.S....
Importing Oncology Trials From China, or Other Single Foreign Countries, for Consideration of U.S. Regulatory Approvals
In a commentary published in The Lancet Oncology, Harpreet Singh, MD, and Richard Pazdur, MD, both of the Oncology Center of Excellence at the U.S. Food and Drug Administration (FDA), warned against the increasing number of oncology drug development programs based wholly or predominantly on data...
Study Identifies Factors Impacting Adherence to Oral Medications for Metastatic Breast Cancer
A recent study published by Conley et al in Breast Cancer Research and Treatment aimed to evaluate factors that influence the ability of people with metastatic breast cancer to adhere to their prescribed regimen of oral anticancer medication. Researchers found that multiple factors affected...
Study Finds Patients With Lung Cancer Demonstrated Psychological Resilience in the Face of the COVID-19 Pandemic
Far from being hobbled by fears of COVID-19, patients with lung cancer actually showed less depression and anxiety during the pandemic than their healthy peers, according to results from a new study by Arrato et al published in JNCCN–Journal of the National Comprehensive Cancer Network. Researchers ...
Guideline Update Highlights the Importance of Shared Decision-Making Regarding the Use of Adjuvant Therapy in Stage II Colon Cancer
ASCO has published updated guidance on the use of adjuvant therapy in the management of stage II colon cancer, providing clinicians with a newer evidence-based framework that can be used in shared decision-making with patients.1 Need for Updated Guidance “How to approach patients with stage II...
Use of Consolidation Durvalumab and Adjuvant Osimertinib Among Key Recommendations in New ASCO Guideline on Stage III NSCLC Treatment
A new ASCO guideline provides key recommendations for the evaluation and management of stage III non–small cell lung cancer (NSCLC). Recommendations made by the ASCO expert panel cover evaluation and staging of NSCLC, neoadjuvant and adjuvant therapies, and the management of unresectable ...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in the Russian Federation
The Russian Federation is the largest country in the world, extending from Eastern Europe to Northern Asia and the Pacific Ocean. The population of more than 140 million people is unevenly distributed across the country.1 As a result, Russia has high spatial inequality in terms of accessibility of...
RxPONDER Trial: Another Step in Defining Which Patients With Breast Cancer May Be Spared Adjuvant Cytotoxic Chemotherapy
As reported by Kalinsky et al and summarized in this issue of The ASCO Post, an interim analysis of the phase III RxPONDER trial showed that the addition of adjuvant chemotherapy to endocrine therapy improved invasive disease–free survival among premenopausal—but not postmenopausal—women with...
Expert Point of View: Charles Shapiro, MD
Charles Shapiro, MD, Professor of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, commented on the study findings. “MA.32 is a large, randomized placebo-controlled trial of metformin in over 3,600 women with invasive breast cancer. The rationale for...
Metformin Added to Standard Adjuvant Chemotherapy Fails to Improve Outcomes in Early Breast Cancer
The addition of metformin, a drug commonly used to treat type 2 diabetes, to standard adjuvant treatment failed to improve invasive disease–free survival or overall survival for hormone receptor–positive or –negative breast cancer, according to the results of a large landmark trial led by the...
Expert Point of View: Angela DeMichele, MD, MSCE
Angela DeMichele, MD, MSCE, the Alan and Jill Miller Professor in Breast Cancer Excellence at the Perelman School of Medicine of the University of Pennsylvania in Philadelphia, commented on NIMBUS1 for The ASCO Post. She said obtaining information on tumor mutational burden is simple, as it is part ...
Expert Point of View: Debu Tripathy, MD, and Hope S. Rugo, MD, FASCO
The ASCO Post asked Debu Tripathy, MD, Professor and Chair of Medical Breast Oncology at The University of Texas MD Anderson Cancer Center, Houston, and Hope S. Rugo, MD, FASCO, Professor of Medicine, Director of Breast Oncology and Clinical Trials Education at the University of California San...
Mindfulness in Pediatric and Adolescent Patients With Cancer
Guest Editor’s Note: Mindfulness has gained immense popularity in recent years. Growing evidence suggests the benefits of mindfulness-based practices, which include concentration meditation and guided imagery, for managing symptoms associated with cancer and its treatments. In this article,...
Expert Point of View: Hope S. Rugo, MD, FASCO
The discussant of KEYNOTE-522 at the 2021 San Antonio Breast Cancer Symposium, Hope S. Rugo, MD, FASCO, Professor of Medicine and Director of Breast Oncology and Clinical Trials Education at the University of California San Francisco Comprehensive Cancer Center, commented: “We are clearly making...
Expert Point of View: Joshua Brody, MD
Joshua Brody, MD, Director of the CLL/Lymphoma Immunotherapy Program, Icahn School of Medicine at Mount Sinai, New York, who was not involved in these trials, commented: “CLL is an extremely prevalent disease affecting nearly 200,000 patients in the United States. Most patient do not require...
Expert Point of View: Anthony El-Khoueiry, MD
Anthony El-Khoueiry, MD, Member of the Section of Gastrointestinal Cancers, Director of the phase I program, and Associate Professor of Clinical Medicine at the Keck School of Medicine of the University of Southern California and USC Norris Comprehensive Cancer Center, said the findings of the...
HIMALAYA Trial: First-Line Tremelimumab Plus Durvalumab Improves Overall Survival in Unresectable Hepatocellular Carcinoma
Patients with advanced, unresectable hepatocellular carcinoma may be gaining another first-line treatment option. In the global phase III HIMALAYA trial, a single priming dose of tremelimumab plus regular-interval durvalumab significantly improved overall survival, according to Ghassan K....
Amit Maity, MD, PhD, to Lead Department of Radiation Oncology at the University of Utah
Huntsman Cancer Institute (HCI) and University of Utah Health welcome Amit Maity, MD, PhD. Dr. Maity will serve as Professor and Chair of the Department of Radiation Oncology for the Spencer Fox Eccles School of Medicine at the University of Utah. Dr. Maity is a physician-scientist who currently...
Expert Point of View: Nilofer Azad, MD
Nilofer Azad, MD, Professor of Oncology at Johns Hopkins University School of Medicine and Co-Director of Cancer Genetics and Epigenetics at the Sidney Kimmel Comprehensive Cancer Center, Baltimore, was invited to discuss the results of the phase III TOPAZ-1 study, which found an overall survival...
Oncology Drugs With Accelerated Approval: Is It Time for a Reset?
Regulations that are developed by the U.S. Food and Drug Administration (FDA) must have some shelf-life before revisions are considered. The FDA has several mechanisms to provide patients with more rapid access to medicines. One such pathway is accelerated approval. Backward Glance at Accelerated...
AACR Releases Report on the Impact of COVID-19 on Cancer Research and Patient Care
On February 9, the American Association for Cancer Research (AACR) released the AACR Report on the Impact of COVID-19 on Cancer Research and Patient Care. According to findings contained within the report, patients with cancer are not only at an increased risk for developing severe COVID-19, but...
Adverse Event Rates After Two Doses of mRNA COVID-19 Vaccine in Patients With vs Without Cancer
New research published by Shulman et al in JNCCN—Journal of the National Comprehensive Cancer Network confirmed that mRNA vaccines for COVID-19 are just as safe for people with cancer as they are for cancer-free individuals. Researchers from a single institution tracked short-term side effects from ...
Can An Intelligent Vacuum-Assisted Biopsy Algorithm Reliably Identify Patients With Breast Cancer Who Have a Pathologic Complete Response to Neoadjuvant Therapy?
In a study reported in the Journal of Clinical Oncology, Pfob et al developed a machine learning algorithm–based (intelligent) vacuum-assisted biopsy model that could identify patients with pathologic complete response (ypT0 and ypN0) to neoadjuvant therapy for breast cancer who may be able to...
Mirek Fatyga, PhD, on NSCLC: New Data on Stereotactic Body Radiotherapy vs Conventionally Fractionated Radiotherapy
Mirek Fatyga, PhD, of Mayo Clinic Arizona, discusses his findings on overall survival in patients with locally advanced non–small cell lung cancer who are treated with stereotactic body radiotherapy or conventionally fractionated radiotherapy. He notes that a high dose of > 50 Gy to the...
Predictive Model for Severe Fatigue After Breast Cancer Diagnosis
In a study reported in the Journal of Clinical Oncology, Di Meglio et al developed a predictive model for severe fatigue after a diagnosis of breast cancer. Study Details The study involved data on patients with stage I to III breast cancer included in the prospective multicenter CANcer TOxicity...
Role of CECR2 Gene in Advanced Triple-Negative Breast Cancer
A new study published by Zhang et al in Science Translational Medicine shows inhibition of the CECR2 gene may prevent triple-negative breast cancer from advancing or metastasizing. The discovery is an early step in finding new therapeutics for triple-negative breast cancer, one of the most...
Expert Point of View: Rona Yaeger, MD
Rona Yaeger, MD, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, New York, offered her thoughts on the findings of Morris et al for the combination regimen of encorafenib, cetuximab, and nivolumab in patients with microsatellite-stable BRAF V600E–mutated metastatic...
Expert Point of View: Demetris Papamichael, MB, BS
The invited discussant of the SOLSTICE trial1 was Demetris Papamichael, MB, BS, Consultant Medical Oncologist at the Bank of Cyprus Oncology Centre and Associate Professor at St. George’s Hospital and Medical School, University of London. He said that although the study concluded...
SOLSTICE Trial: Trifluridine/Tipiracil Plus Bevacizumab in Metastatic Colorectal Cancer
For the treatment of metastatic colorectal cancer in patients unfit for intensive chemotherapy, trifluridine/tipiracil plus bevacizumab as first-line therapy was no more effective than capecitabine plus bevacizumab, investigators from the phase III SOLSTICE trial reported in a European Society for...
FDA Investigating Possible Increased Risk of Death With Lymphoma Treatment Umbralisib
The U.S. Food and Drug Administration (FDA) is investigating a possible increased risk of death associated with umbralisib (Ukoniq), a kinase inhibitor including PI3K-delta and CK1-epsilon, approved to treat marginal zone and follicular lymphomas. The FDA determined that initial findings from the...
CancerCare Offers Patients Financial Assistance for Transportation, Pet Care
Financial assistance may be available for some individuals with cancer from CancerCare, a nonprofit organization helping people cope with and manage the emotional and practical challenges of cancer. Two assistance programs tailored to specific individuals are available to meet financial challenges...
Risk-Standardized Mortality Rates as Quality Proxy for Surgical Oncology
In a German study reported in the Journal of Clinical Oncology, Baum et al found that risk-standardized mortality rates may be a better-quality proxy for complex oncologic surgeries than hospital volume. As stated by the investigators, “Despite a long-known association between annual hospital...
Thierry André, MD, on Esophagogastric Adenocarcinoma: New Findings on Nivolumab and Ipilimumab
Thierry André, MD, of Sorbonne University and Saint-Antoine Hospital, discusses phase II results from the GERCOR NEONIPIGA study, which suggests neoadjuvant therapy with nivolumab and ipilimumab may be associated with a high pathologic complete response rate in patients with localized...
Can Weight Loss in Adulthood Reduce the Risk of Developing Colorectal Adenomas?
Weight loss for adults, particularly those who are overweight or obese, may reduce their risk of developing a type of polyp that may lead to colorectal cancer, according to a new study published by He et al in JNCI Cancer Spectrum. Losing weight from early to late adulthood (up to the mid-70s)—at...
Can Postsurgical Monoclonal Antibody Treatment Reduce HER2-Positive Early-Stage Breast Cancer Recurrence?
Treating women diagnosed with a certain type of early-stage breast cancer with the monoclonal antibody trastuzumab after surgery may reduce the risk of the cancer returning, according to a report published by Ali et al in Scientific Reports. The research team from the University of Saskatchewan...
Expert Point of View: Hanno R. Hock, MD, PhD
In an interview with The ASCO Post, Hanno R. Hock, MD, PhD, Assistant Professor of Medicine at Harvard Medical School and Massachusetts General Hospital, highlighted the study’s “very nice response rate” and “encouraging data” while also noting that a pediatric-based treatment regimen in fit adults ...
Kerryn Reding, PhD, MPH, RN, Daughter of Health-Care Workers, Chooses a Career in Breast Cancer Survivorship
Kerryn Reding, PhD, MPH, RN—whose research focuses on reducing cancer incidence and improving survival, with particular interests in lifestyle interventions and biomarkers of risk—was born in Australia, but her family moved to Iowa when she was a toddler. “Both of my parents were in health care. My ...
President Biden Reignites Cancer Moonshot
As Vice President, in 2016, Joe Biden launched the Cancer Moonshot with the mission to accelerate the rate of progress against cancer. The cancer and patient community and medical researchers responded with energy and ingenuity. On February 2, President Biden announced the reigniting of the Cancer ...
Addition of Sugemalimab to Platinum-Based Chemotherapy for Metastatic Squamous or Nonsquamous NSCLC
In the Chinese phase III GEMSTONE-302 trial reported in The Lancet Oncology, Caicun Zhou, MD, and colleagues found that the addition of the PD-L1 inhibitor sugemalimab to platinum-based chemotherapy improved progression-free survival in the first-line treatment of metastatic squamous or nonsquamous ...
TERAVOLT Study Identifies Seven Factors That Increase Mortality Risk for Patients With Lung Cancer Infected With COVID-19
The risk of death for patients with SARS–CoV-2 infection and thoracic cancer is based on seven major determinants, according to research published by Alessio Cortellini, MD, in the Journal of Thoracic Oncology. TERAVOLT Data The researchers analyzed data from the Thoracic Cancers International...
Melissa Amy Lumish, MD, on Rectal Cancer: PD-1 Blockade for Mismatch Repair–Deficient Disease
Melissa Amy Lumish, MD, of Memorial Sloan Kettering Cancer Center, discusses new findings showing a 100% complete response rate to PD-1 blockade alone among the first 11 patients with locally advanced mismatch repair–deficient rectal cancer treated with this approach. None of the patients required...
Challenges for Oncologists as They Reach Retirement Age
In 2014, The ASCO Post spoke with Mark J. Clemons, MB BS, BMedSci, MSc, MD, FRCP, FRCPC, of Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada, about the retirement challenges faced by many oncologists. With market demand expected to exceed supply of oncologists soon, it is clear retirement is...
FDA Approves New Label Update for CAR T-Cell Therapy Axicabtagene Ciloleucel
On January 31, the FDA approved an update to the prescribing information for axicabtagene ciloleucel (Yescarta) to include use of prophylactic corticosteroids across all approved indications. Axicabtagene ciloleucel is now the first and only chimeric antigen receptor (CAR) T-cell therapy with...
Study Examines Head and Neck Cancer Incidence in Black Populations Around the World
Researchers have found that disparities in the incidence of head and neck cancer are driven by behavioral and environmental risk factors rather than race. They demonstrated this in the first-ever study to compare head and neck cancer incidence in Black patients in the United States, the Caribbean,...
FDA Approves Second COVID-19 Vaccine
On January 31, the U.S. Food and Drug Administration (FDA) approved a second COVID-19 vaccine, which has been known as the Moderna COVID-19 vaccine, for the prevention of COVID-19 in individuals aged 18 years and older; the approved vaccine will be marketed as Spikevax. “The FDA’s approval of [the...
